Selective antisense compounds and uses thereof

Abstract

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.

1 .- 40 . (canceled) 
     
     
         41 . A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the linked nucleosides comprise at least 8 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 24, 3, 67, 70, 71, 73, 77, 80, 91, or 577. 
     
     
         42 . The compound of  claim 41 , wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO. 1. 
     
     
         43 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 24. 
     
     
         44 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 3. 
     
     
         45 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 67. 
     
     
         46 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 70. 
     
     
         47 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 71. 
     
     
         48 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 73. 
     
     
         49 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 77. 
     
     
         50 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 80. 
     
     
         51 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 91. 
     
     
         52 . The compound of  claim 42 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 577. 
     
     
         53 . The compound of  claim 43 , wherein the oligonucleotide has a eeeekk-d7-kke sugar motif. 
     
     
         54 . The compound of  claim 44 , wherein the oligonucleotide has a sugar motif selected from among: ekk-d-f-kke, ekk-d7-kkeee, ekk-d2-h-d6-kke, ekk-d3-z-d5-kke, ekk-d6-z-d2-kke, ekk-d8-z-kke, or ekk-d9-kke. 
     
     
         55 . The compound of  claim 45 , wherein the oligonucleotide has a ekek-d9-keee sugar motif. 
     
     
         56 . The compound of  claim 46 , wherein the oligonucleotide has a eeeeek-d7-kke sugar motif. 
     
     
         57 . The compound of  claim 47 , wherein the oligonucleotide has a eeeekk-d7-kee sugar motif. 
     
     
         58 . The compound of  claim 48 , wherein the oligonucleotide has a eeeeek-d7-kee sugar motif. 
     
     
         59 . The compound of  claim 49 , wherein the oligonucleotide has a eeeeek-d7-eeeeee sugar motif. 
     
     
         60 . The compound of  claim 50 , wherein the oligonucleotide has a eek-d7-eeeeeeeee sugar motif. 
     
     
         61 . The compound of  claim 51 , wherein the oligonucleotide has a ekek-d9-keke sugar motif. 
     
     
         62 . The compound of  claim 52 , wherein the oligonucleotide has a ekk-d2-z-d6-kke sugar motif. 
     
     
         63 . A method of ameliorating a symptom of Huntington's disease, comprising administering an oligomeric compound of  claim 41  to an animal in need thereof.